
Silence Therapeutics (SLN) P/E Ratio
P/E Ratio as of Feb 3, 2026: -2.90
Average-3.26
Median-3.33
Minimum-3.55
Maximum-2.88
-2.90
0.78 (21.20%)past month
The P/E ratio for Silence Therapeutics (SLN) is -2.90 as of Feb 3, 2026. This represents a decrease of -7.05% compared to its 12-month average P/E ratio of -3.12. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Silence Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Silence Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Silence Therapeutics to industry peers.
Silence Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Silence Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Silence Therapeutics to industry peers.
Silence Therapeutics (SLN) P/E Ratio Insights
See Silence Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Silence Therapeutics (SLN)
Order type
Buy in
Order amount
Est. shares
0 shares
Silence Therapeutics (SLN) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Dec 1, 2025 | $6.59 | -3.94 |
| Nov 3, 2025 | $6.61 | -3.95 |
| Oct 1, 2025 | $5.10 | -3.05 |
| Sep 2, 2025 | $4.77 | -2.85 |
| Aug 1, 2025 | $6.17 | -3.69 |
| Jul 1, 2025 | $5.92 | -3.54 |
| Jun 2, 2025 | $5.73 | -3.43 |
| May 1, 2025 | $4.01 | -2.40 |
| Apr 1, 2025 | $2.42 | -1.45 |
| Mar 3, 2025 | $4.32 | -2.58 |
| Feb 3, 2025 | $5.06 | -3.03 |
| Jan 2, 2025 | $7.19 | -4.30 |
Silence Therapeutics (SLN) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2026 | -2.90 | -20.33% |
| 2025 | -3.64 | -11.65% |
| 2024 | -4.12 | -66.01% |
| 2023 | -12.12 | +45.32% |
| 2022 | -8.34 | -36.14% |
| 2021 | -13.06 | — |
FAQs About Silence Therapeutics (SLN) P/E ratio
The latest P/E ratio of Silence Therapeutics (SLN) is -2.90, as of Feb 3, 2026. This is calculated based on its current stock price and earnings per share (EPS).
Silence Therapeutics’s last 12-month average P/E ratio is -3.12, compared to its current P/E ratio of -2.90. This reflects a decrease of -7.05%.
Silence Therapeutics’s current P/E ratio of -2.90 is lower than its last 12-month average P/E of -3.12. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Silence Therapeutics’s average P/E ratio over the last 3 years is -7.67. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Silence Therapeutics’s average P/E ratio over the last 5 years is -8.8. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.